Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.…
Sight Sciences (SGHT) Stock Gets Fair Value Boost After Q3 Beat And Guidance Raise
Sight Sciences (NASDAQ: SGHT) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 186 employees.
The shares were at 10.18 USD on 20 November 2026, up 103.6% over 52 weeks. Its 52-week range is 3.378 USD to 11.60 USD: the price is 12.2% below the high and 201.4% above the low.
Its market capitalisation is 565.79M USD.
Sight Sciences reports return on equity of -60.1%, an operating margin of -20.2% and revenue up 25.2% year over year.
It holds more cash than debt, a net cash position of 35.30M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 12.25 USD is 20.3% above the current price. The next earnings report is expected on 3 March 2027.